Agilent s Microarray Platform Surfs on Surge in Revenues and Orders for Q2 | GenomeWeb

Agilent Technologies, considered the No. 2 manufacturer of microarrays, on Monday reported overall net earnings that represented a $250 million turnaround in the span of a year.

The company, which only months ago was instituting stringent expense management and a third round of layoffs since 2001, had net income of $104 million in its second fiscal quarter ending April 30, compared to a loss of $146 million for the same quarter in 2003. Orders across the four business groups of the Palo Alto, Calif.-based company were up some 24 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.